Drugs / MK-2828
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07431866 | Mar → Jun 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07435194 | Mar → Aug 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07348237 | Mar → Sep 2026 | chronic renal failure syndrome, end stage renal failure, impaired renal function disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07089784 | Sep 2025 → May 2026 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-2828 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07348237 ↗ |
| Route | Oral | “Oral capsule of MK-2828 taken once per day for 28 days.” NCT07089784 ↗ |